SSR1

Summary

SSR1 (signal sequence receptor subunit 1, HGNC:11323) is a protein-coding gene on chromosome 6p24.3, encoding Translocon-associated protein subunit alpha (P43307). TRAP proteins are part of a complex whose function is to bind calcium to the ER membrane and thereby regulate the retention of ER resident proteins.

The signal sequence receptor (SSR) is a glycosylated endoplasmic reticulum (ER) membrane receptor associated with protein translocation across the ER membrane. The SSR consists of 2 subunits, a 34-kD glycoprotein encoded by this gene and a 22-kD glycoprotein. This gene generates several mRNA species as a result of complex alternative polyadenylation. This gene is unusual in that it utilizes arrays of polyA signal sequences that are mostly non-canonical. Multiple transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 6745 — RefSeq curated summary.

At a glance

• GWAS associations: 10
• Clinical variants (ClinVar): 39 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_003144

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11323
Approved symbol	SSR1
Name	signal sequence receptor subunit 1
Location	6p24.3
Locus type	gene with protein product
Status	Approved
Aliases	TRAPA
Ensembl gene	ENSG00000124783
Ensembl biotype	protein_coding
OMIM	600868
Entrez	6745

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 12 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000244763, ENST00000397511, ENST00000462112, ENST00000474597, ENST00000475213, ENST00000479365, ENST00000479485, ENST00000483409, ENST00000488834, ENST00000489567, ENST00000650389, ENST00000916205, ENST00000916206, ENST00000916207, ENST00000916208

RefSeq mRNA: 2 — MANE Select: NM_003144 NM_001292008, NM_003144

CCDS: CCDS4499, CCDS78109

Canonical transcript exons

ENST00000244763 — 8 exons

Exon	Start	End
ENSE00001155537	7295392	7295485
ENSE00001155542	7297923	7298001
ENSE00001155548	7298747	7298823
ENSE00001155552	7301310	7301572
ENSE00001546762	7281143	7289931
ENSE00003632826	7303550	7303637
ENSE00003643320	7309917	7310029
ENSE00003842382	7313042	7313199

Expression profiles

Bgee: expression breadth ubiquitous, 302 present calls, max score 99.61.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 132.0305 / max 2419.4395, expressed in 1826 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
71613	126.3440	1825
71610	1.8842	1083
71612	1.1571	602
71605	1.0166	415
71611	1.0002	589
71609	0.5621	263
71616	0.0663	34

Top tissues by expression

303 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
corpus epididymis	UBERON:0004359	99.61	gold quality
caput epididymis	UBERON:0004358	99.55	gold quality
trabecular bone tissue	UBERON:0002483	99.49	gold quality
parotid gland	UBERON:0001831	99.39	gold quality
tibia	UBERON:0000979	99.38	gold quality
skin of hip	UBERON:0001554	99.33	gold quality
cauda epididymis	UBERON:0004360	99.31	gold quality
mucosa of sigmoid colon	UBERON:0004993	99.30	gold quality
germinal epithelium of ovary	UBERON:0001304	99.24	gold quality
gingiva	UBERON:0001828	99.23	gold quality
gingival epithelium	UBERON:0001949	99.20	gold quality
seminal vesicle	UBERON:0000998	99.18	gold quality
decidua	UBERON:0002450	99.14	gold quality
parietal pleura	UBERON:0002400	99.13	gold quality
oral cavity	UBERON:0000167	99.04	gold quality
pigmented layer of retina	UBERON:0001782	99.04	gold quality
retina	UBERON:0000966	99.02	gold quality
choroid plexus epithelium	UBERON:0003911	99.01	gold quality
pleura	UBERON:0000977	99.00	gold quality
esophagus squamous epithelium	UBERON:0006920	98.99	gold quality
superficial temporal artery	UBERON:0001614	98.98	gold quality
mammary duct	UBERON:0001765	98.96	gold quality
squamous epithelium	UBERON:0006914	98.96	gold quality
colonic mucosa	UBERON:0000317	98.95	gold quality
visceral pleura	UBERON:0002401	98.89	gold quality
islet of Langerhans	UBERON:0000006	98.84	gold quality
mammalian vulva	UBERON:0000997	98.78	gold quality
bone marrow cell	CL:0002092	98.77	gold quality
epithelium of esophagus	UBERON:0001976	98.75	gold quality
epithelium of mammary gland	UBERON:0003244	98.75	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 6.

Experiment	Marker?	Max mean expression
E-GEOD-130473	yes	20912.94
E-MTAB-9467	yes	48.62
E-HCAD-1	yes	44.14
E-CURD-122	yes	22.06
E-MTAB-6678	yes	8.06
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): SPI1

miRNA regulators (miRDB)

301 targeting SSR1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-10401-5P	99.99	65.79	948
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-5688	99.96	73.23	4504

Literature-anchored findings (GeneRIF, showing 1)

• RP11156L14.1 regulates SSR1 expression by competitively binding to miR548ao3p in hypopharyngeal squamous cell carcinoma. (PMID:33000261)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ssr1	ENSDARG00000101627
mus_musculus	Ssr1	ENSMUSG00000021427
rattus_norvegicus	Ssr1	ENSRNOG00000014165
drosophila_melanogaster	l(1)G0320	FBGN0028327
caenorhabditis_elegans	trap-1	WBGENE00022122

Protein

Protein identifiers

Translocon-associated protein subunit alpha — P43307 (reviewed: P43307)

Alternative names: Signal sequence receptor subunit alpha

All UniProt accessions (8): A0A3B3IRT8, C9IZQ1, C9J3L8, C9J5W0, C9JBX5, C9JY01, E9PAL7, P43307

UniProt curated annotations — full annotation on UniProt →

Function. TRAP proteins are part of a complex whose function is to bind calcium to the ER membrane and thereby regulate the retention of ER resident proteins. May be involved in the recycling of the translocation apparatus after completion of the translocation process or may function as a membrane-bound chaperone facilitating folding of translocated proteins.

Subunit / interactions. Heterotetramer of TRAP-alpha, TRAP-beta, TRAP-delta and TRAP-gamma. Interacts with palmitoylated calnexin (CALX), the interaction is required for efficient folding of glycosylated proteins.

Subcellular location. Endoplasmic reticulum membrane.

Domain organisation. Shows a remarkable charge distribution with the N-terminus being highly negatively charged, and the cytoplasmic C-terminus positively charged.

Miscellaneous. Seems to bind calcium.

Similarity. Belongs to the TRAP-alpha family.

Isoforms (2)

UniProt ID	Names	Canonical?
P43307-1	1	yes
P43307-2	2

RefSeq proteins (2): NP_001278937, NP_003135* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005595	TRAP_alpha	Family

Pfam: PF03896

UniProt features (23 total): sequence conflict 7, modified residue 3, glycosylation site 2, topological domain 2, region of interest 2, compositionally biased region 2, signal peptide 1, chain 1, splice variant 1, sequence variant 1, transmembrane region 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
9N9J	ELECTRON MICROSCOPY	3.2
9YGY	ELECTRON MICROSCOPY	4.1
8B6L	ELECTRON MICROSCOPY	7.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P43307-F1	76.20	0.46

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 260, 268, 247

Glycosylation sites (2): 136, 191

Function

Pathways and Gene Ontology

Reactome pathways

8 pathways

ID	Pathway
R-HSA-1799339	SRP-dependent cotranslational protein targeting to membrane
R-HSA-381038	XBP1(S) activates chaperone genes
R-HSA-2262752	Cellular responses to stress
R-HSA-381070	IRE1alpha activates chaperones
R-HSA-381119	Unfolded Protein Response (UPR)
R-HSA-392499	Metabolism of proteins
R-HSA-72766	Translation
R-HSA-8953897	Cellular responses to stimuli

MSigDB gene sets: 314 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_DN, TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCTAL_NORMAL_UP, MODULE_52, BORCZUK_MALIGNANT_MESOTHELIOMA_UP, ACTACCT_MIR196A_MIR196B, REACTOME_UNFOLDED_PROTEIN_RESPONSE_UPR, GRUETZMANN_PANCREATIC_CANCER_DN, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GNF2_BNIP2, MIDORIKAWA_AMPLIFIED_IN_LIVER_CANCER, chr6p24, ENK_UV_RESPONSE_KERATINOCYTE_UP, SHEPARD_CRASH_AND_BURN_MUTANT_UP, AAGCCAT_MIR135A_MIR135B

GO Biological Process (2): cotranslational protein targeting to membrane (GO:0006613), positive regulation of cell population proliferation (GO:0008284)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (3): endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
Translation	1
IRE1alpha activates chaperones	1
Cellular responses to stimuli	1
Unfolded Protein Response (UPR)	1
Cellular responses to stress	1
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein targeting to membrane	1
cell population proliferation	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
binding	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1284 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SSR1	SSR2	P43308	999
SSR1	SSR3	Q9UNL2	998
SSR1	SSR4	P51571	978
SSR1	SEC61A1	P38378	613
SSR1	RPL31	P12947	604
SSR1	RPN1	P04843	572
SSR1	SEC63	Q9UGP8	564
SSR1	RPN2	P04844	539
SSR1	STT3A	P46977	513
SSR1	CANX	P27824	488
SSR1	STT3B	Q8TCJ2	487
SSR1	HSP90B1	P14625	451
SSR1	SEC61B	P38390	450
SSR1	RREB1	Q92766	447
SSR1	DERL2	Q9GZP9	442

IntAct

152 interactions, top by confidence:

A	B	Type	Score
EGFR	HSP90AA1	psi-mi:“MI:0914”(association)	0.820
CANX	SSR1	psi-mi:“MI:0915”(physical association)	0.770
SSR1	CANX	psi-mi:“MI:0914”(association)	0.770
CANX	SSR1	psi-mi:“MI:0914”(association)	0.770
EZH2	EPOP	psi-mi:“MI:0914”(association)	0.730
NRBP1	TSC22D2	psi-mi:“MI:0914”(association)	0.730
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
ERBB3	PIK3R2	psi-mi:“MI:0914”(association)	0.700
SEC61A1	CANX	psi-mi:“MI:0914”(association)	0.690
PKN3	ARHGAP10	psi-mi:“MI:0914”(association)	0.680
CFTR	HAX1	psi-mi:“MI:0914”(association)	0.610
CANX	PGRMC1	psi-mi:“MI:0914”(association)	0.570
SEC61B	SSR1	psi-mi:“MI:0915”(physical association)	0.560
RPL13	RPLP1	psi-mi:“MI:0914”(association)	0.530
RPN1	APBB1	psi-mi:“MI:0914”(association)	0.530
FLVCR1	TNFRSF10B	psi-mi:“MI:0914”(association)	0.530
ILK	ILVBL	psi-mi:“MI:0914”(association)	0.530
ERBB2	NDUFA4	psi-mi:“MI:0914”(association)	0.530
SSR1	SERPINA1	psi-mi:“MI:0915”(physical association)	0.520
SERPINA1	SSR1	psi-mi:“MI:0915”(physical association)	0.520
NRAS	ESYT2	psi-mi:“MI:2364”(proximity)	0.480

BioGRID (545): SSR1 (Affinity Capture-MS), SSR1 (Affinity Capture-MS), SSR1 (Affinity Capture-MS), ATP5C1 (Co-fractionation), CYC1 (Co-fractionation), DDOST (Co-fractionation), PHB (Co-fractionation), SSR1 (Co-fractionation), SSR1 (Co-fractionation), SSR1 (Co-fractionation), SSR1 (Co-fractionation), SSR1 (Co-fractionation), SSR1 (Co-fractionation), SSR1 (Co-fractionation), SSR1 (Co-fractionation)

ESM2 similar proteins: A5D8P8, A5PJA8, A6QLP7, A7E2Z9, A9SV59, B5DDX6, E2RQ08, F1QR43, F1R777, F4JVN6, O12940, O18756, O64614, O94923, P04843, P07153, P16967, P43307, P45433, P51571, P53815, Q04499, Q05AW9, Q07984, Q0IHY5, Q0J6P7, Q2M146, Q2TBX5, Q3UFM5, Q4R4T0, Q4R5V2, Q5R4X4, Q5REH6, Q5RFB6, Q5TYV0, Q5ZJT0, Q62186, Q6P7K5, Q7ZV50, Q8BXQ2

Diamond homologs: A6QLP7, P16967, P43307, P45433, P53815, Q54R45, Q5R4X4, Q7TPJ0, Q9CY50, P45434

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
SSR1	“form complex”	“TRAP complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 169 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Signaling by ERBB2 ECD mutants	6	31.7×	3e-06
Constitutive Signaling by EGFRvIII	5	28.1×	3e-05
Signaling by ERBB2 TMD/JMD mutants	7	26.2×	1e-06
GRB2 events in ERBB2 signaling	5	25.0×	5e-05
Signaling by ERBB2 KD Mutants	7	23.3×	2e-06
SHC1 events in ERBB2 signaling	6	22.5×	1e-05
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	5	22.5×	7e-05
SRP-dependent cotranslational protein targeting to membrane	17	13.4×	6e-12

GO biological processes:

GO term	Partners	Fold	FDR
cytoplasmic translation	10	12.9×	7e-06
translation	12	8.6×	1e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

39 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	23
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2180 predictions. Top by Δscore:

Variant	Effect	Δscore
6:7289871:T:C	donor_gain	1.0000
6:7295390:A:AC	donor_gain	1.0000
6:7295391:C:CT	donor_gain	1.0000
6:7295391:CT:C	donor_gain	1.0000
6:7295391:CTG:C	donor_gain	1.0000
6:7295391:CTGA:C	donor_gain	1.0000
6:7295391:CTGAT:C	donor_gain	1.0000
6:7295484:CG:C	acceptor_gain	1.0000
6:7295486:C:CC	acceptor_gain	1.0000
6:7298002:C:CC	acceptor_gain	1.0000
6:7298742:CTT:C	donor_loss	1.0000
6:7298743:TTACG:T	donor_loss	1.0000
6:7298744:T:TC	donor_loss	1.0000
6:7298745:A:AC	donor_gain	1.0000
6:7298745:ACGT:A	donor_loss	1.0000
6:7298746:C:CG	donor_gain	1.0000
6:7298746:CGTTT:C	donor_gain	1.0000
6:7298819:TTGCC:T	acceptor_gain	1.0000
6:7298820:TGCC:T	acceptor_gain	1.0000
6:7298820:TGCCC:T	acceptor_loss	1.0000
6:7298821:GCCCT:G	acceptor_loss	1.0000
6:7298822:CC:C	acceptor_gain	1.0000
6:7298822:CCCTG:C	acceptor_loss	1.0000
6:7298823:CC:C	acceptor_gain	1.0000
6:7298823:CCTG:C	acceptor_loss	1.0000
6:7298824:C:A	acceptor_loss	1.0000
6:7298824:C:CC	acceptor_gain	1.0000
6:7298825:T:A	acceptor_loss	1.0000
6:7301304:TCTTA:T	donor_loss	1.0000
6:7301305:CTTA:C	donor_loss	1.0000

AlphaMissense

1877 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:7301329:A:G	L175P	1.000
6:7301486:A:G	S123P	1.000
6:7301503:A:T	V117D	1.000
6:7295418:A:G	I256T	0.999
6:7295420:C:A	W255C	0.999
6:7295420:C:G	W255C	0.999
6:7295422:A:G	W255R	0.999
6:7295422:A:T	W255R	0.999
6:7298786:A:T	V194D	0.999
6:7298801:A:T	V189D	0.999
6:7301341:A:G	L171S	0.999
6:7301380:A:G	F158S	0.999
6:7301387:A:G	Y156H	0.999
6:7301399:C:G	A152P	0.999
6:7301443:A:G	F137S	0.999
6:7301445:A:C	N136K	0.999
6:7301445:A:T	N136K	0.999
6:7301449:T:G	Q135P	0.999
6:7301479:C:G	R125P	0.999
6:7301482:A:G	F124S	0.999
6:7301488:G:T	A122D	0.999
6:7301489:C:G	A122P	0.999
6:7301498:A:G	S119P	0.999
6:7301533:A:G	F107S	0.999
6:7301542:A:G	L104P	0.999
6:7297975:C:T	G216D	0.998
6:7297976:C:G	G216R	0.998
6:7298780:A:T	V196D	0.998
6:7298797:G:C	F190L	0.998
6:7298797:G:T	F190L	0.998

dbSNP variants (sampled 300 via entrez): RS1000047214 (6:7286871 C>A), RS1000080247 (6:7312953 C>T), RS1000235310 (6:7307950 T>C), RS1000322103 (6:7307389 T>C), RS1000387694 (6:7290333 C>G), RS10004 (6:7310026 A>G), RS1000490243 (6:7308242 C>G,T), RS1000710862 (6:7284091 A>C,G,T), RS1000723452 (6:7304141 T>C), RS1000862945 (6:7314195 G>A,T), RS1000988204 (6:7312540 G>A), RS1001081846 (6:7313944 C>T), RS1001298723 (6:7312725 G>A), RS1001377966 (6:7308456 C>A), RS1001507700 (6:7303061 G>A)

Disease associations

OMIM: gene MIM:600868 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST002352_15	Type 2 diabetes	1.000000e-09
GCST004894_131	Type 2 diabetes	2.000000e-08
GCST004894_56	Type 2 diabetes	1.000000e-09
GCST006291_86	Spherical equivalent or myopia (age of diagnosis)	1.000000e-09
GCST006467_1	Ewing sarcoma	1.000000e-18
GCST007847_124	Type 2 diabetes	3.000000e-08
GCST010118_49	Type 2 diabetes	2.000000e-14
GCST010702_91	Subcortical volume (MOSTest)	1.000000e-08
GCST010703_226	Brain morphology (MOSTest)	9.000000e-13
GCST012227_222	Hip circumference adjusted for BMI	5.000000e-08

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004847	age at onset
EFO:0004346	neuroimaging measurement
EFO:0008039	BMI-adjusted hip circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066162 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

1 potent at pChembl≥5 of 5 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.31	IC50	490	nM	MOLIBRESIB

PubChem BioAssay actives

1 with measured affinity, of 10 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2178997: Inhibition of SSR1 (unknown origin) incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	ic50	0.4900	uM

CTD chemical–gene interactions

59 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	7
Cyclosporine	increases expression	4
bisphenol S	decreases methylation, increases expression	3
bisphenol A	decreases expression, affects expression	2
cobaltous chloride	decreases expression	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
aristolochic acid I	decreases expression	1
FR900359	decreases phosphorylation	1
bisphenol F	increases expression	1
methylmercuric chloride	increases expression	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
sodium arsenate	decreases expression	1
salinomycin	decreases expression	1
trichostatin A	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
nivalenol	decreases expression	1
methacrylaldehyde	affects cotreatment, decreases expression, increases abundance	1
tamibarotene	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
deguelin	decreases expression	1
4-chloro-N-((4-(1,1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide	decreases expression	1
bisphenol B	increases expression	1
abrine	decreases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases reaction, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
eprenetapopt	affects expression	1
jinfukang	decreases expression	1
LDN 193189	affects cotreatment, decreases expression	1
bisphenol AF	increases expression	1

ChEMBL screening assays

7 unique, capped per target: 7 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652540	Binding	Binding affinity to human SSR1 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.